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Abstract
Background: Prevalence of neurocognitive impairment in HIV-1 infected patients is reported to be high. Whether this is a
result of active HIV-related neurodegeneration is unclear. We examined axonal injury in HIV-1 patients by measuring the
light subunit of neurofilament protein (NFL) in CSF with a novel, sensitive method.
Methods: With a cross-sectional design, CSF concentrations of neurofilament protein light (NFL) (marker of neuronal injury),
neopterin (intrathecal immunoactivation) and CSF/Plasma albumin ratio (blood-brain barrier integrity) were analyzed on
CSF from 252 HIV-infected patients, subdivided into untreated neuroasymptomatics (n = 200), HIV-associated dementia
(HAD) (n = 14) and on combinations antiretroviral treatment (cART) (n = 85), and healthy controls (n = 204). 46 HIV-infected
patients were included in both treated and untreated groups, but sampled at different timepoints. Furthermore, 78
neuroasymptomatic patients were analyzed before and after treatment initiation.
Results: While HAD patients had the highest NFL concentrations, elevated CSF NFL was also found in 33% of untreated
neuroasymptomatic patients, mainly in those with blood CD4+ cell counts below 250 cells/mL. CSF NFL concentrations in
the untreated neuroasymptomatics and treated groups were equivalent to controls 18.5 and 3.9 years older, respectively.
Neopterin correlated with NFL levels in untreated groups while the albumin ratio correlated with NFL in both untreated and
treated groups.
Conclusions: Increased CSF NFL indicates ongoing axonal injury in many neuroasymptomatic patients. Treatment decreases
NFL, but treated patients retain higher levels than controls, indicating either continued virus-related injury or an aging-like
effect of HIV infection. NFL correlates with neopterin and albumin ratio, suggesting an association between axonal injury,
neuroinflammation and blood-brain barrier permeability. NFL appears to be a sensitive biomarker of subclinical and clinical
brain injury in HIV and warrants further assessment for broader clinical use.
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Introduction
HIV invades the central nervous system (CNS) shortly after
transmission where it can then be detected in cerebrospinal fluid
(CSF) throughout the course of untreated systemic infection in
most patients including the majority of patients without neuro-
logical symptoms in the earlier phase of infection [1,2]. Despite the
lack of symptoms, this infection is accompanied by elevated
markers of intrathecal immunoactivation, including elevated CSF
white blood cell counts and neopterin concentrations [2,3].
Without treatment, approximately 20–30% of patients develop
HIV associated dementia (HAD), characterized by cognitive and
motor impairment with major impact of functional capacity and
lifespan [4]. With the introduction of combination antiretroviral
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therapy (cART), the incidence of HAD has been markedly
reduced in developed countries, and even severely impaired
patients have improved after treatment initiation [5–8]. However,
despite virological suppression, long-term treated patients may
complain of memory difficulties, mental slowing, attention deficits
and other symptoms of neurological impairment, and a number of
studies have found the prevalence of milder forms of HIV-
associated neurocognitive disorders (HAND) including asymptom-
atic neurocognitive impairment (ANI) and HIV-associated mild
neurocognitive disorder (MND) to be as high as 35–69 percent [9–
11].
Currently, the formal diagnosis of HAND, including particu-
larly its milder forms, relies on the results of neuropsychological
testing compared to normative controls, and hence confounded by
other conditions affecting performance and may be overestimated
using currently recommended methods [9,10] [12]. Importantly,
these testing methods do not distinguish residual from ongoing
brain injury, an issue with particular implications for antiviral or
other therapies, since approaches to ongoing injury are different
from those for static, residual damage. For this reason, there is a
potential role for more objective approaches to evaluating ongoing
CNS disease, including CSF biomarkers and functional brain
imaging that provide complementary approaches to this problem
[13]. While several CSF biomarkers of neural injury have been
studied in HIV-infected patients, perhaps the most promising is
the light subunit of the neurofilament protein (NFL) [14,15]. This
major structural component of myelinated axons is essential to
maintain axonal caliber and to facilitate effective nerve conduction
[16], and its concentration in CSF provides a sensitive marker of
CNS injury in a number of neurological diseases [17–19]. Earlier
studies have reported substantially increased levels of CSF NFL in
patients with HAD, and mild elevations in some untreated,
neurologically asymptomatic patients, mainly in those with low
CD4 cell counts, indicating subclinical brain injury [14]. Elevated
CSF NFL has been found in some patients up to two years before
onset of HAD and thus has the potential to serve as a predictive
biomarker of symptomatic progression [15]. Finally, normalization
of CSF NFL has been shown both in patients with and without
HAD after initiation of cART, [20].
Recently, a new and more sensitive immunoassay for measuring
CSF NFL has been introduced. This assay is more sensitive, and in
particular, has a broader dynamic range at the lower level of
biological concentrations, CSF NFL can now be measured in most
normal subjects allowing the detection of smaller increases in
pathological states. In this study we applied this new assay to
examine the frequency of neuronal injury at different stages of
untreated systemic HIV infection and the effects of antiretroviral
treatment. Because of the natural increase of CSF NFL
concentration with age in the uninfected population, we also
examined the relation of HIV-associated NFL changes to subject
age. We further examined whether CSF NFL was associated with
the level of systemic and CNS viral replication as measured by
plasma and CSF HIV RNA concentration, with systemic
immunosuppression as reflected in blood CD4+ T cell counts,
with intrathecal immune activation measured by CSF neopterin
concentrations[21] and blood-brain barrier (BBB) dysfunction
assessed by the CSF:blood albumin ratio [22].
Methods
Study design and subjects
The report describes two related studies, one cross-sectional and
the other a longitudinal cohort design. Both used archived
specimens and data from volunteer subjects from two academic
centers: Sahlgrenska University Hospital in Gothenburg, Sweden
and San Francisco General Hospital, California, USA. All subjects
were studied under research protocols approved by institutional
review boards of the Sahlgrenska Academy and University of
California Committee on Human Research and followed guide-
lines of the Helsinki declaration. Informed verbal consent was
obtained from all patients and documented in their respective
patient file, a procedure accepted by the ethic committees. Written
consent was not required by the ethic committees. All patients
received written and verbal study information.
In the cross-sectional study, 252 HIV-infected subjects were
segregated into 6 subgroups (Table 1): Four groups of untreated
patients without overt neurological disease (henceforth referred to
as neuroasymptomatic, or NA) subdivided according to levels of
blood CD4+ T-cells into ,50 CD4+ T-cells per mL (n = 42), 50–
199 cells per mL (n = 49), 200–349 cells per mL (n = 52) and .350
(n = 57) cells per mL; a group of HAD patients (n = 14); one group
on suppressive cART with plasma HIV-RNA ,50 copies/mL for
at least one year (n = 85). Forty-six subjects were included in both
untreated and treated groups sampled at different time points,
usually several years apart (median 5.9 years, IQR 2.6–9.2). We
also included healthy HIV-negative controls (n = 204), table 1.
Lumbar puncture was done as part of the clinical follow-ups, at
least annualy. Patients were defined as neuroasymptomatic if they
were without symptoms or signs of neurological or cognitive
disability on clinical examination and follow-up. Neuropsycholog-
ical examinations were performed only on subjects with symptoms
or complaints consistent with neurocognitive disorder. The
diagnosis of HAD was based on CDC and American Academy
of Neurology Task Force Criteria using standard laboratory and
clinical evaluations [9,23,24].
The longitudinal cohort study included 78 neuroasymptomatic
patients who were treatment-naive or had been off treatment for
.6 months. CSF samples were analyzed before and after
treatment initiation, with a median time of 15 weeks (interquartile
range, IQR 14–23). Subject characteristics are also shown in
Table 1.
Analytical methods
CSF samples were submitted to low-speed centrifugation to
remove cells, aliquoted, and frozen to 270uC within 1 hour of
performing the lumbar puncture for storage until analysis. CSF
NFL protein was measured in the Laboratory of Neurochemistry
at the University of Gothenburg using a novel, sensitive sandwich
ELISA method (NF-lightH ELISA kit) as described by the
manufacturer (UmanDiagnostics AB, Umea˚, Sweden). The lower
limit of quantification was 50 ng/L and intra- and inter-assay
coefficients of variation were 4?1–13%. The upper normal refence
limits of CSF NFL were ,380 ng/L (18–30 years), ,560 (30–39
years), ,890 (40–59 years), ,1850 (.59 years); these limits were
established using 108 CSF samples from neurologically healthy
control individuals aged 18–76 years.
HIV RNA in CSF and plasma was measured using the Roche
Amplicor Monitor version 1.5, Roche Taqman assay version 1 or
2 (Hoffman La-Roche, Basel, Switzerland) or Abbott RealTime
HIV-1 assay (Abbott Laboratories. Abbott Park, Illinois, U.S.A.).
The lowest limit of detection was defined as 20 copies per mL.
Neopterin was analyzed in CSF using a commercially available
immunoassay (BRAHMS, Berlin, Germany) with an upper normal
reference value of 5.8 nmol/L [21]. Other measurements,
including blood CD4+ T-cell counts, CSF WBC and CSF and
blood albumin values to calculate the CSF:blood ratio, were
performed in the local clinical laboratories.
CSF NFL in HIV-1 Infection
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Statistical analysis
The Mann-Whitney test was used to compare variables between
independent groups. Wilcoxon matched-pairs signed rank test was
used to compare CSF NFL levels before and after treatment. The
relationship between log10 CSF NFL levels and CD4+ cell counts
were analyzed with non-linear regression. The relationship
between log10 CSF NFL levels and age in controls and the partly
overlapping treated and untreated groups were analyzed with a
linear mixed effects model.
Predictors of log10 CSF NFL were analyzed by multiple linear
regression analysis with backward elimination in treated and
untreated groups separately. In these analyses WBC and HIV
RNA were log transformed and CD4+ T-cell count was inverse
transformed (1/(CD4 + 45.3)) based on the previous non-linear
regression. General descriptive statistics are presented as median
and interquartile range (IQR). All statistical analyses were
performed using IBM SPSS Statistics version 20 or Prism
version 5 (Graphpad Software Inc, La Jolla, CA).
Results
Cross sectional study
252 HIV-positive patiens subdivided into three groups were
studied: Neuroasymptomatics, further stratified into four groups
according to levels of blood CD4 cells, HAD and patients on
suppressive antiretroviral treatment. 204 HIV-negative subjects
served as controls. For further subject characteristics, see table 1.
CSF NFL concentrations were higher in subjects with HAD than
all other groups including the untreated subjects with equivalently
low CD4+ T-cell counts (p,0.001). Higher levels of CSF NFL
were also found in subjects with a CD4+ T-cell count below
50 cells/mL compared to the three untreated groups with higher
CD4+ T-cell counts (p,0.001) (Figure 1).
Using the laboratory age-related cutoffs for CSF NFL described
earlier, nearly all (13/14, 93%) of the HAD patients had elevated
CSF NFL concentrations. Additionally, elevated CSF NFL
concentrations were found in a substantial number of the
untreated neuroasymptomatic subjects, particularly those with
lower blood CD4+ T cell counts. Thus, 29/42 (69%) of those with
CD4+ T-cell count below 50 cells/mL and 15/49 (31%) with 50–
199 CD4+ cells/mL had elevated concentrations, and even 11/52
(21)% of subjects with 200–349 CD4 cells and 11/57 (19%) of
those with CD4 cell counts above 350 cells/mL were also
elevated—indicating a high level of clinically unappreciated
Table 1. Background subject characteristics.
Groups N Age Plasma HIV RNA CSF HIV RNA Blood CD4+ T cells
Median years (IQR) Median Log10 (IQR) Median cells/mL (IQR)
Cross-sectional study
NA, CD4,50 42 39 (36–49) 5.37 (4.88–5.61) 3.12 (2.30–3.81) 23 (10–40)
NA, CD4 50–199 49 39 (34–48) 4.92 (4.49–5.52) 4.92 (4.49–5.52) 130 (97–164)
NA, CD4 200–349 52 40 (33–50) 4.88 (4.30–5.35) 4.88 (4.30–5.35) 252 (230–300)
NA, CD4 .350 57 42 (34–48) 4.30 (3.74–4.85) 3.43 (2.92–3.92) 490 (400–630)
HAD 14 47 (38–53) 5.02 (4.73–5.38) 5.02 (4.73–5.38) 127 (35–160)
Treated-suppressed 85 47 (38–53) 1.30 (1.30–1.30) 1.30 (1.30–1.30) 530 (330–708)
HIV negative 204 36 (28–52) NA NA NA
Longitudinal cohort study
All subjects 78 40 (34–47) 5.16 (3.98–5.57) 3.91 (3.25–4.44) 190 (70–270)
Normal CSF NFL 52 40 (34–46) 4.95 (4.33–5.39) 4.07 (3.41–4.60) 210 (125–275)
Elevated CSF NFL 26 42 (36–49) 5.43 (5.02–5.88) 3.71 (2.73–4.39) 150 (2
NA: Not available.
doi:10.1371/journal.pone.0088591.t001
Figure 1. Cross-sectional analysis of CSF NFL in HIV disease.
Included were 14 subjects diagnosed with HIV-associated dementia
(HAD); HIV positive neuroasymptomatic subjects (NA) without antiret-
roviral treatment stratified according to levels of blood CD4 T-cells ,50
(n = 42), 50–199 (n = 49), 200–349 (n = 52) and.350 (n = 57); 85 subjects
on combination antiretroviral treatment (ART) for at least one year and
plasma HIV-RNA ,50 copies/ml and 204 HIV seronegative volunteers
(HIV-neg). CSF NFL concentrations were higher in patients with HAD
compared to all other groups. Elevated levels of CSF NFL was also found
in subjects with a CD4+ T-cell count below 50 cells/mL compared to
groups in higher CD4+ T-cell count strata. Whiskers represent full range
doi:10.1371/journal.pone.0088591.g001
CSF NFL in HIV-1 Infection
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ongoing CNS injury that varied with degree of systemic disease
progression. By comparison, in the treated group and HIV-
negative subjects the frequency was much lower, 7/85 (8%) and 4/
204 (2%), respectively.
Correlations of CSF NFL with CD4+ T-cell counts. The
influence of disease progression was more directly shown as a
strong correlation of CSF NFL with the blood CD4+ T-cell counts
in neuroasymptomatic untreated patients, p =,0.001. A loess
regression suggested an inverse transformation of CD4+ T-cell
counts (Figure 2). Visual inspection revealed a rapid decline with
increasing CD4+ T-cell counts that flattens out at around
250 cells/mL. CSF NFL concentrations in patients with HIV-
associated dementia (HAD) diagnosis, marked with red color in
figure 2, were significantly higher also compared to neuroasymp-
tomatic patients with equivalently low CD4+ T-cell counts,
p,0.001, suggesting additional factors contributing to this more
severe and clinically overt disease.
No significant correlation was found between CD4+ T-cell
counts and CSF NFL within the treated, virologically suppressed
group.
Correlations of CSF NFL with age and treatment
effects. Since CSF NFL increases with age in uninfected
populations, we analyzed the differences between treated and
untreated subjects and HIV negatives with age as covariate. This
resulted in a model of three parallel regression lines (Figure 3). The
group differences can be expressed as the corresponding age
increase needed for an equivalent difference in the two HIV-
infected groups compared to the controls.. We found that the CSF
concentration of NFL in the untreated group, despite their lack of
symptoms, was equivalent to subjects 18.5 years older than the
HIV negative controls (p,0.001). While treatment reduced these
concentrations, CSF NFL concentration in the population on
cART was equivalent to HIV-negatives 3.9 years older (p,0.01),
figure 3. The 95% prediction interval for CSF NFL levels in HIV-
negative controls corresponded well to the age-related cut-offs
provided by the laboratory.
Multivariate analysis. A multiple non-linear regression
analysis that included CSF NFL versus age, CD4+ T-cell counts,
CSF WBC, CSF:blood albumin ratio, plasma and CSF HIV RNA
and CSF neopterin was performed on both untreated and treated
patients. Univariate and multivariate analyses are shown in
Table 2. In the treated group CD4+ T-cell nadir and pre-
treatment HIV RNA in CSF and plasma were also included in the
analysis. In the untreated asymptomatic groups, age (n = 200),
CD4+ T-cell counts (n = 200), CSF neopterin (n = 188), CSF WBC
count (n = 200) and CSF/plasma albumin ratio (n = 200) all stood
out as possible independent predictors related to CSF NFL in the
univariate analysis. These predictors were also statistically
significant with adjusted estimates in the multivariate analysis.
By contrast the plasma and CSF viral loads were not significant
predictors. In the treated group, only age (n = 85), pre cART
plasma viral load (n = 63) and CSF/plasma albumin ratio (n = 85)
were found as independent predictors of CSF NFL concentration
(Table 2).
Longitudinal Cohort study
Overall, CSF NFL levels decreased in 63% of the patients
(n = 49) from a pre-treatment CSF NFL median level of 520 ng/L
(IQR 310–1070) to 475 ng/L (IQR 315–782.5) after initiation of
cART (p,0.01) (Figure 4). Of the 26 (33%) subjects with elevated
Figure 2. Correlations with CD4 T-cell counts and CSF NFL. A
loess regression (dotted line) suggested an inverse transformation of
CD4+ T-cell counts. Visual inspection reveals a rapid decline with
increasing CD4+ T-cell counts that flattens out at around 250 cells/mL.
The relationship between log10 CSF NFL levels and CD4+ cell counts
were fitted with non-linear regression using the function Log CSF NFL
= b1 + b2/(CD4 + b3) (filled line). CSF NFL concentrations in patients
with HIV-associated dementia (HAD) diagnosis, marked with red color in
the figure were significantly elevated also compared to untreated
neuroasymptomatic patients with equivalently low CD4+ T-cell counts,
p,0.001.
doi:10.1371/journal.pone.0088591.g002
Figure 3. CSF NFL related to age and treatment effect. Since CSF
NFL increases with age, we analyzed the group differences with a linear
mixed effects model with age as covariate. This implies a model with
three parallel regression lines where the group differences correspond
to the vertical distances between the regression lines. The group
differences can be expressed as the corresponding age increase needed
for an equivalent difference. The 95% prediction interval of CSF NFL
levels of HIV-negative controls is demonstrated as dotted lines (Neg
95% PI). Concentrations of CSF NFL in neuroasymptomatic untreated
HIV-infected subjects (No ART) were equivalent to those of HIV-negative
subjects (negative) who were 18.5 years older (p,0.001). CSF NFL
concentrations in the treated group (ART) were equivalent to those of
HIV-negative subjects who were 3.9 years older (p,0.01).
doi:10.1371/journal.pone.0088591.g003
CSF NFL in HIV-1 Infection
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levels of CSF NFL at baseline, 21 (81%) exhibited a reduction in
their CSF NFL levels after treatment, from a pre-treatment
median level of 1415 ng/L (IQR 1023–2715) to a posttreatment
level of 825 ng/L (IQR 662.5–1220) after a median of 15 weeks of
treatment (p,0.01), figure 4. Nine (35%) had normalized by the
posttreatment assessment. In one patient, an unexpected increase
from 2350 ng/L to 17310 ng/L was observed. This patient had
systemic Mycobacterium Avium Complex infection and developed
systemic immune reconstitution inflammatory syndrome (IRIS)
after starting cART which may have also involved the CNS.
Although CSF NFL decreased in some patients with normal
baseline CSF NFL (n = 52), overall there was no significant
reduction for the group as a whole. All patients with normal CSF
NFL concentrations at baseline remained normal except for three
subjects who exhibited increases to abnormal levels from 470 to
1500 ng/L, from 290 to 2460 ng/L and from 420 to 990 ng/L,
respectively (reference range for their ages is ,890 ng/L). These
changes were not accompanied by notable neurological symptoms
and all three showed decrease in plasma and CSF HIV RNA and
exhibited increases in their CD4 counts after treatment. The
patient with the highest CSF NFL increase developed a cutaneous
vasculitis, along with a proximal venous thrombosis requiring
anticoagulants and high doses of corticosteroids. No symptoms
and signs associated with immune reconstitution or other disorders
to explain the elevations were noted. One patient was lost to
follow-up.
Discussion
Our results provide compelling evidence supporting the value of
CSF NFL as a biomarker of axonal disruption in untreated
patients with HIV infection. They show that CSF NFL is not only
a sensitive biomarker of symptomatic HAD, but also demonstrates
that a substantial number of untreated asymptomatic patients
suffer subclinical CNS injury. The prevalence of this injury
increases as systemic disease progresses and blood CD4+ T cells
fall. Thus, CSF NFL was strongly inversely correlated with CD4+
T-cell counts. Indeed, a clear majority of patients with counts
below 50 cells/mL exhibited elevation of this neuronal marker in
CSF and nearly half of those with counts below 200 had abnormal
levels showing that subclinical injury in more advanced disease is
common.
This common, presumably chronic, brain injury at reduced cell
counts provides one explanation for the reported high prevalence
of neurological symptoms and reduced cognitive performance in
treated patients with lower CD4+ T cell nadirs [25–27] as it leaves
behind a legacy of irreversible damage prior to treatment initiation
underlying subsequent function. The fact that we did not find a
correlation between CSF NFL and CD4+ T-cell nadir, itself, is
consistent with this earlier injury rather than the nadir count
predisposing to subsequent ongoing pathology. Moreover, the
substantial proportion of patients with even higher CD4+ T-cell
counts (.200 cells/mL) with elevated CSF NFL levels may imply a
less common and less severe, but still significant, neuropathological
insult even in subjects with relatively preserved immunity.
Although the prognostic meaning of these generally milder
Table 2. Univariate correlation (left columns) and multiple
linear regression (right columns) determining predictors of
log10 CSF NFL in HIV-infected neuroasymptomatic patients
with and without antiretroviral treatment.
Univariate Multivariate
Variable N Std b (r) P Std badj Padj
No treatment
Age 200 0.35 ,0.001 0.26 ,0.001
Blood CD4* 200 0.43 ,0.001 0.36 ,0.001
CSF neopterin 188 0.31 ,0.001 0.23 ,0.001
Log CSF WBC 200 20.27 ,0.001 20.17 0.009
Albumin ratio 200 0.33 ,0.001 0.33 ,0.001
Log plasma VL 198 0.29 ,0.001 NS NS
Log CSF VL 199 20.036 0.62 NS NS
Treated-
suppressed
Age 85 0.66 ,0.001 0.57 ,0.001
Blood CD4* 85 0.089 0.42 NS NS
CSF neopterin 77 0.062 0.59 NS NS
Log CSF WBC 85 20.051 0.65 NS NS
Albumin ratio 85 0.4 ,0.001 0.26 0.004
Log pre ART plasma
VL
63 0.16 0.23 0.23 0.013
Log pre ART CSF VL46 20.31 0.23 NS NS
Log CSF VL 85 20.091 0.41 NS NS
Nadir CD4* 61 0.023 0.023 NS NS
*CD4+ T-cell count was inverse transformed (1/(CD4+45?3) NS =Not significant.
doi:10.1371/journal.pone.0088591.t002
Figure 4. CSF NFL levels before-after combination antiretrovi-
ral treatment (cART) initiation. Overall CSF NFL levels decreased in
63% of the patients after initiation of cART (p,0.01), demonstrated as a
lower CSF NFL geometric mean (dotted line) after initiation of cART.
33% of the patents had elevated levels of CSF NFL at baseline and 81%
of those exhibited reduction in their CSF NFL levels after treatment
(p,0.01). 35% of patients with pathological CSF NFL at baseline
normalized their levels (green colored). Those with normal CSF NFL at
baseline exhibited no significant reduction in CSF NFL (blue colored).
Three patients with normal baseline CSF NFL exhibited elevated levels
of CSF NFL after cART initiation (red colored).
doi:10.1371/journal.pone.0088591.g004
CSF NFL in HIV-1 Infection
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e88591
elevated CSF NFL levels in asymptomatic HIV infected patients
was not studied here, a previous study showed that increased CSF
NFL was found to be predictive of HAD development in
neuroasymptomatic patients compared to CD4-matched controls
in a case-control study [15]. It is therefore likely that asymptomatic
patients with increased CSF NFL suffer subclinical HIV-related
neurodegeneration that results in cumulative injury and later
disability in some patients. While treatment of those with elevated
NFL may reverse this, it may leave a legacy of compromised brain
integrity and function. These results therefore provide strong,
albeit uncontrolled, support for early treatment initiation to
prevent subsequent neurological dysfunction.
CSF NFL increases with age in the absence of HIV infection.
Though the mechanisms underlying this increase are not
established, it may confound analysis of the consequences of the
HIV infection itself and potential treatment effects on CSF NFL
over time. However, when comparing neuroasymptomatic
untreated patients as a whole to HIV-negative controls and the
HIV-positive group on cART, CSF NFL was higher in untreated
subjects regardless of age, equivalent to 18.5 years older HIV
negative controls. Fortunately, this elevation is largely reversible.
Yet, and perhaps of greater interest, levels of CSF NFL in the
treated and virologically suppressed group remained significantly
higher than those of the HIV-negative population, a difference
equivalent to the addition of 3.9 years of life in this group. This
finding might reflect a discrete, continuous neuroinflammation
and axonal degradation due to ongoing, yet undetected, infection
or continued local infection with mild, but important neuropatho-
genic effect. Or it might indicate an effect of the prior injury that is
similar to the effect of aging on the metabolism of NFL and their
neuronal substrate. Apart from neuroinflammatory and neurode-
generative diseases, such as MS [28,29] and frontotemporal
dementia[28,29], NFL is also increased in acute damage to the
CNS, for example following diffuse axonal injury or stroke [30,31].
The increase is generally interpreted as reflecting a direct,
destructive effect on NFL-rich large caliber axons. Although this
is likely in our study as well, we cannot exclude that the noticed
increase of NFL in part depends on other factors, such as
reparative processes, in which injured axons are slowly removed
leading to a prolonged release of NFL into the CSF. Since NFL
was analyzed in CSF, it reflects CNS concentrations, although a
minimal part might derive from peripheral nerve roots in
connection with the CNS.
Future studies of both aging and treated HIV infection need to
address the sources of this elevated CSF NFL, whether due to
increased release or turnover of NFL or, alternatively, reduced
clearance from CSF. Additionally, it will be important to assess
correlations of elevated CSF NFL in treated patients with detailed
neuropsychological test performance in addition to pretreatment
neurological status to dissect the effects of earlier injury from
evidence of ongoing damage in determining post-treatment
neurological status and CSF NFL.
Earlier studies have shown that microglia/macrophage activa-
tion, reflected by increased levels of CSF neopterin is an important
factor in HIV neuropathogenesis [21]. In untreated patients, CSF
neopterin concentrations are almost always elevated and increase
progressively as immunosuppression worsens and blood CD4+ T-
cell counts drops [21]. In our data, CSF neopterin and CSF WBC
count were strongly and independently correlated with CSF NFL
in untreated patients. This suggests that the intrathecal inflam-
matory reaction is important for the development of axonal
degradation in HIV infection and support the neuropathogenic
role of macrophage/microglial activation.
CSF neopterin was not found to be a predictive factor for CSF
NFL in treated patients. However, CSF albumin ratio was an
independent predictor for CSF NFL in both treated and untreated
HIV infected subjects. Increased CSF albumin ratio reflects a
compromised BBB with increased permeability of serum proteins
and other substances into the brain. Perivascular inflammation
and BBB dysfunction are frequent findings in patients with HAD
[30–32] and our data suggest that increased permeability across
the BBB may be pathogenically linked to axonal injury in HIV.
Several reports indicate that milder forms of HAND are fairly
common also in HIV infected patients on effective treatment
[11,33], [10]. These reports are however based solely on
neuropsychological testing. Data from this study give more
objective indications that also virologically suppressed patients
are at risk of CNS damage. However, confounders that we are not
aware of could be present and it is important to point out that only
a small fraction of treated subjects had pathological levels of CSF
NFL.
There are a number of limitations of this study. It involved a
convenience sample studied through archived samples. Impor-
tantly, extensive neuropsychological testing required for Frascati
criteria diagnosis [9] was not performed. The cross-sectional study
also has its limitations in assessing treatment effects, though the
longitudinal cohort study shows that NFL decreases after
treatment initiation, thereby clearly linking NFL elevations with
CNS HIV infection.
Conclusions
The findings of this study support the value of CSF NFL as an
independent marker of CNS damage at different stages of HIV
infection. We present data indicating subclinical brain injury
reflected by levels of CSF NFL in a substantial proportion of
untreated HIV infected patients. The most important influencing
factors in addition to subject age were CD4+ T-cell counts, CSF
neopterin levels, CSF WBC counts and CSF/plasma albumin
ratio, reflecting the importance of systemic disease progression,
immune activation and blood brain barrier dysfunction in HIV
neuropathogenesis. Antiretroviral treatment has a substantial
effect on intrathecal immunoactivation and neurodegeneration,
but even virologically suppressed patients exhibited higher levels of
CSF NFL than HIV negative controls, suggesting ongoing low-
grade injury or an aging effect of HIV infection that is not fully
reversed by treatment. To better understand the prognostic
meaning of fluctuations of CSF NFL in HIV disease and to
evaluate this marker as a diagnostic tool for HIV-associated
neurocognitive disorders, future prospective studies with concur-
rent neuropsychological testing will be important.
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